For context, the dual agonist tirzepatide is studied in SURMOUNT ( NEJM , 2022) and SURMOUNT-OSA ( NEJM , 2024)
mBio 2 , e00271-10 (2011)
In February 2026, full results from the REDEFINE 2 study showed CagriSema achieving 23% weight loss at 84 weeks but falling short of its primary endpoint under the treatment policy estimand (which measures efficacy across all patients regardless of whether they completed treatment, rather than only those who remained on it)
Some patients notice visible changes to their weight by the end of the first or third month, while others experience more gradual, significant weight loss after six months
doi: 10.1007/s10803-015-2432-7 30
He explains what your numbers mean and why specific recommendations matter for your body not just generic advice you could find on Google